Hubei is the first province to complete the provincial supplement, which varieties have been transferred in?

Source: medicine magic cube 2017-08-30 the supplementary plans of all provinces in China are still in bloom, but Hubei Province has not announced the plans, which directly and silently bear fruit, becoming the first province in China to complete the provincial supplementary task Hubei has temporarily settled down, but has completed a major event for many years Before that, we classified the varieties to be added to the province and formed several teams Today, let's take a look at which varieties have been transferred to Hubei Overall situation in 2017, 295 varieties of class B supplements were transferred into Hubei Province, including 153 Western medicines, 14 with restrictions; 142 Chinese patent medicines, 15 with restrictions The three Western medicines, ashurevir, enterovirus 71 inactivated vaccine (Vero cell) and sodium folinate, are limited to work-related injuries Currently, in the issued scheme, there are provinces that have stated that work-related injury insurance drugs are not limited by the adjustment index Although it is not mentioned in Hubei Province, it seems that after subtracting these three varieties, 292 drugs are transferred into Hubei Province, which is consistent with the quantity restricted by the state But this time Hubei Province has given a relatively loose and favorable policy on the dosage form In the past, it was necessary to take up the quota for the situation that the dosage forms could not be combined This time, levonorgestrel included three categories - oral regular release dosage form, intrauterine contraceptive system, levonorgestrel II implant are all within the scope of medical insurance; enoxacin and gatifloxacin also have multiple dosage forms that can be used in medical insurance; and lafutidine, for example, has regular release dosage form and granules this time At present, lafutidine granules are exclusively produced by Hubei Guangji Pharmaceutical Co., Ltd In 2010, the province's supplementary varieties accounted for the largest proportion The newly added class B drugs were matched with the medical insurance catalogue of Hubei Province in 2010 91 western medicine varieties were matched successfully and 78 Chinese patent medicine varieties were matched successfully, which means that a total of 169 drugs were postponed from the reimbursement catalogue in 2010 This small team accounts for nearly 60% of the quota These postponed varieties also include Xuebijing injection, one of the eight varieties that failed in the national negotiation, which is more limited to the second-class and above medical institutions than before However, compared with the previous notice documents on implementation issued by Xinjiang, it is relatively mild to block these historical varieties outside the door Other varieties originally covered by medical insurance According to the available data, in 2011, according to the policy, Hubei Province included 16 composite drugs in the scope of medical insurance reimbursement Among these drugs, 7 antihypertensive drugs entered the national medical insurance catalog in 2017, and the remaining 4 drugs were included in this supplement They are alendronate sodium, vitamin D3, estradiol / estradiol, digestroprostone, metformin, rosiglitazone and perindopril, indapamide In addition, during the urban-rural integration at the beginning of this year, Hubei plans to add some reimbursed varieties in the new rural cooperative medical system catalog to the 2010 catalog Some of these varieties are also included in the 2017 national catalog The remaining three varieties are included in the new class B of Hubei Province: vitamin AD, zinc gluconate and dizosin In addition to the above-mentioned new varieties that were clearly included in the scope of medical insurance, there are 55 other drugs listed in the first supplement list in China, two of which have attracted the attention of the editor, namely letetrexed and albumin paclitaxel These two varieties are not cheap, especially the latter, which can be said to be very expensive In addition, both drugs are exclusive This listing shows that even expensive cancer drugs have opportunities in local supplements Leiti trasser is the exclusive product of Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd It can't be used in the patients with advanced colorectal cancer In 2010, it entered the supplement of B-type medical insurance in five provinces and cities The bid price in 2013 in Hubei Province was 1701.1 yuan for a single unit The new paclitaxel for injection (albumin binding type) is suitable for the treatment of metastatic breast cancer which failed in combination chemotherapy or breast cancer which recurred within 6 months after adjuvant chemotherapy The limitation of this inclusion is its indication The latest bid price of Alb taxol in Hubei Province is 5854.89 yuan Previously, paclitaxel liposomes from green leaves were included in 44 varieties negotiated by the state Once included, it will have a great impact on the market of white protein paclitaxel However, it was not included finally The state requires provinces and cities not to consider it any more In this case, ALB paclitaxel is back to the game It's a bit of a twists and turns At present, the relevant rights and interests of this variety in China have been handed over to Baiji Shenzhou, and lenalidomide has been included in the medical insurance catalog through national negotiations If the albumin paclitaxel can provide good news in each province in succession, the transaction between Baiji Shenzhou and Xinji will be more and more colorful On Friday, September 1, Japan will officially implement the 2017 new national health insurance catalogue and 36 negotiated varieties in more than 10 provinces and cities The provincial supplement will also come intensively this year In 2017, the label of the medical industry was heavily labeled with the word "medical insurance" Let's look forward to the final report of the medical insurance intensive year.